Fundraising Fox

Helicore

Southbury, US · Founded 2020 · 5 known investors

Find your way into Helicore

72 people in our graph share verified history with the Helicore team — schools, employers, funds. One of them is your warm intro.

Andrea Cambriaunlockedknows Kevin Russ · together at Villanova University (overlapped)
×2knows the team · via Villanova University
×9knows the team · via T-Mobile

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.

BiotechHealthtech

Founders & leadership

KRKevin Russ
Kevin RussinChief Executive OfficerHe brings over 30 years of experience in program and project management across wireless communications and infrastructure development, with expertise in site acquisition, permitting, RF design, and 5G deployment, along with certifications as a PMP and PgMP project manager.
WK
Waters KelloggNamed on SEC filing
LB
Lucas B. TurnerNamed on SEC filing
JD
Joshua DotsonNamed on SEC filing
HK
Holger KoehlerNamed on SEC filing
CB
Charles BridgeNamed on SEC filing

Investors · 5

Longitude CapitalMenlo Park · $10M – $30M
OrbiMedNew York · $1M – $75M
Versant Venturesreported · 2 sourcesSan Francisco · $250K – $5M
Wellington ManagementreportedBoston · $5M – $50M

Also in the syndicate · 1

Versantlead

Funding

SEC filings, press & company announcements

$2M disclosed across 1 of 3 rounds · 2020–2025

▶$2MraisedApr 2020 · 1 investors · Telecommunications
Rule 506(b)
Officers, directors & promoters on the filing
  • Waters KelloggDirector
  • Lucas B. TurnerDirector
  • Joshua DotsonDirector
  • Kevin RussExecutive Officer, Director
  • Holger KoehlerDirector
  • Charles BridgeDirector
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2M
First sale
Apr 2020
Incorporated
Limited Liability Company, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Helicore Biopharma Launches from Stealth Mode with $65M Series A Round - PharmaSourcepharmasource.global · Jan 2025Helicore enters obesity drugs arena with $65m funding roundlongevity.technology · Jan 2025Versant invests again in obesity, this time backing Helicore Biopharma | BioPharma Divebiopharmadive.com · Jan 2025Versant Launches Fourth Obesity Startup Helicore to Improve Weight Loss Quality - BioSpacebiospace.com · Jan 2025Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions - BioSpacebiospace.com · Jan 2025Versant launches another obesity biotech with $65M series A and 'clinic-ready' GIP antibodyfiercebiotech.com · Jan 2025

Frequently asked questions

What does Helicore do?
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Who are Helicore's investors?
Helicore's investors include Longitude Capital, OrbiMed, Versant Ventures, Wellington Management.
How much funding has Helicore raised?
Helicore has disclosed $2M raised across 1 of its 3 known rounds.
Where is Helicore headquartered?
Helicore is headquartered in Southbury, US.